Celularity Closes $10M First Tranche of $28M Recapitalization
Celularity secured an initial $10 million financing round as part of a broader recapitalization plan targeting positive operating cash flow by early 2027.
Celularity has closed the first tranche of a planned recapitalization, raising more than $10 million in initial financing as part of a deal that could reach up to $28 million in total proceeds, the company announced via GlobeNewswire.
The cell therapy company said the recapitalization is designed to accelerate growth following what it described as significant operating improvements. Management has set a target of achieving positive operating cash flow by the first quarter of 2027, signaling confidence that the restructured balance sheet will support a path toward financial sustainability.
Read more Darden Restaurants Posts 5.1% Sales Rise in Fiscal Q1 2027 →
The broader $28 million recapitalization framework suggests additional financing tranches remain pending, with the initial closing serving as a foundational step. Companies pursuing staged recapitalizations of this structure typically use early tranches to stabilize operations while subsequent rounds fund expansion or product development milestones.
Celularity operates in the cell-based therapeutics space, a capital-intensive sector where access to growth financing is closely watched by investors and industry observers alike. The company's emphasis on operating improvements ahead of this raise may be intended to strengthen creditor and investor confidence as it pursues the remaining portions of the recapitalization.
Continue reading at GlobeNewswire - Industry News on Financial Services.
